Ensign Peak Advisors
GRCL

Ensign Peak Advisors’s Gracell Biotechnologies Inc. American Depositary Shares GRCL Stock Holding History

Ensign Peak Advisors’s Portfolio GRCL Stock Details GRCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100,741
Closed -$232K – 1794
2022
Q4 		$232K Hold
100,741
– – ﹤0.01% 1736
2022
Q3 		$324K Hold
100,741
– – ﹤0.01% 1673
2022
Q2 		$554K Hold
100,741
– – ﹤0.01% 1419
2022
Q1 		$235K Buy
+100,741
New +$343K ﹤0.01% 1836

Other funds holding GRCL

Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Ensign Peak Advisors's GRCL Position: Q1 2023 in Review

Ensign Peak Advisors sold out of Gracell Biotechnologies Inc. American Depositary Shares (GRCL) in Q1 2023, closing a stake of 100,741 shares — an estimated $232K sold.

Ensign Peak Advisors first reported a position in GRCL in Q1 2022 and held it in 4 quarters. The position peaked at $554K in Q2 2022. 33 funds tracked by Wall St. Rank hold GRCL as of Q1 2023.

  • Ensign Peak Advisors reported no remaining Gracell Biotechnologies Inc. American Depositary Shares position as of Q1 2023 after selling out during the quarter.
  • Ensign Peak Advisors sold 100,741 Gracell Biotechnologies Inc. American Depositary Shares shares in Q1 2023, an estimated $232K.
  • Ensign Peak Advisors first reported a position in Gracell Biotechnologies Inc. American Depositary Shares in Q1 2022 and held it in 4 quarters.
  • Ensign Peak Advisors's Gracell Biotechnologies Inc. American Depositary Shares position peaked at $554K in Q2 2022.
  • 33 funds tracked by Wall St. Rank held Gracell Biotechnologies Inc. American Depositary Shares as of Q1 2023.

Based on Ensign Peak Advisors's 13F filing for Q1 2023, filed 15 May 2023.